Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevuparin study in chronic kidney disease
2024-513864-24-00Phase 2Suspended
- Sponsor
- Modus Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of sevuparin in chronic kidney disease (CKD) (2 arms), sponsored by Modus Therapeutics. Primary endpoints: Pharmacokinetic parameters and Safety assessment. Started Nov 2024; status: suspended.
02
Drugs
sevuparin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-513864-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513864-24-00.